Annual report for Procter & Gamble Health Ltd. for FY-2022
30-08-2022
Procter & Gamble Health Ltd - 500126 - Update On Financial Results
We would like to inform that, we had inadvertently missed attaching cash flow statement while uploading our financial results for the year ended June 30, 2022, approved by the Board at its meeting held today. Request you to kindly note that, initial submission made with the exchange, was made within the prescribed timeline and this is only a revision to the same, due to an inadvertent error as described above. We are hereby re-uploading a full set of results, for your perusal.29-08-2022
Q1FY23 Quarterly Result Announced for Procter & Gamble Health Ltd.
Procter & Gamble Health announced Q1FY23 results: The company recorded sales of Rs 1,092 crore for the fiscal year ending 30 June 2022, up by 10% vs a year ago Profit After Tax (PAT) for the year ended 30th June 2022 is Rs 193 crores, up by 9% Mr. Milind Thatte, Managing Director, P&G; Health India, said, “We have registered consistent growth in revenue in recent quarters in a challenging environment which saw the industry facing headwinds across many categories. This has been a result of extensive efforts across all fronts to improve awareness and accessibility of our superior, quality products, and better serve our customers, consumers, partners and communities. We continued our efforts to create awareness through integrated campaigns encouraging consumers to identify symptoms and seek timely treatment. Our team stepped up on scientific education efforts for healthcare practitioners through accredited symposiums, roundtables and congresses with leading medical and pharmacy associations. This year, we also launched the ‘P&G; Health Academy’, a virtual platform that brings together health experts from across the globe to converge, share and learn. We strengthened our go-to-market strategy through new initiatives that aim to increase reach and distribution. We continued to invest in strengthening public health through our flagship CSR program ‘SEHAT’ (meaning health) with 9 bespoke initiatives, while making strong progress on gender diversity, equality and inclusion through our i-RISE program.” Result PDF29-08-2022
Procter & Gamble Health Ltd - 500126 - Corporate Action-Board approves Dividend
We are pleased to further inform you that the Board of Directors of the Company at its meeting held today, inter alia, have recommended a final dividend of Rs.11.50 per equity share, for the financial year ended June 30, 2022. The dividend shall be paid between November 28, 2022 to December 18, 2022, on approval of the Members at the 55th Annual General Meeting.29-08-2022
Procter & Gamble Health Ltd - 500126 - We Are Pleased To Inform You That At The Meeting Of The Board Of Directors Of The Company Held Today (Commenced At 12.45 Pm And Ended At 2:55 Pm), The Audited Financial Results For Financial Year Ended June 30, 2022 Were Approved. We Are Enclosing Herewith The Following: A. Audited Financial Results For The Financial Year Ended June 30, 2022, As Per Format Prescribed Under Regulation 33 Of Securities Exchange Board Of India (Listing Obligations And Disclosure Requirements), Regulations, 2015; B. Auditor'S Report, In Respect Of The Aforementioned Financial Results, As Furnished By The Statutory Auditors Of The Company; C. Press Release; And D. A Declaration With Respect To Audit Report With Unmodified Opinion To The Aforementioned Audited Financial Results
We are pleased to inform you that at the meeting of the Board of Directors of the Company held today (commenced at 12.45 pm and ended at 2:55 pm), the Audited Financial Results for Financial Year ended June 30, 2022 were approved. We are enclosing herewith the following: a. Audited Financial Results for the Financial Year ended June 30, 2022, as per format prescribed under Regulation 33 of Securities Exchange Board of India (Listing Obligations and Disclosure Requirements), Regulations, 2015; b. Auditor's Report, in respect of the aforementioned Financial Results, as furnished by the Statutory Auditors of the Company; c. Press Release; and d. A declaration with respect to Audit Report with unmodified opinion to the aforementioned Audited Financial Results29-08-2022
Procter & Gamble Health Ltd - 500126 - Board Meeting Outcome for Outcome Of Board Meeting- Audited Financial Results And Dividend
We are pleased to inform you that at the meeting of the Board of Directors of the Company held today (commenced at 12.45 pm and ended at 2:55 pm), the Audited Financial Results for Financial Year ended June 30, 2022 were approved. We are enclosing herewith the following: Audited Financial Results for the Financial Year ended June 30, 2022, as per format prescribed under Regulation 33 of Securities Exchange Board of India (Listing Obligations and Disclosure Requirements), Regulations, 2015; Auditor's Report, in respect of the aforementioned Financial Results, as furnished by the Statutory Auditors of the Company; Press Release; and declaration with respect to Audit Report with unmodified opinion to the aforementioned Audited Financial Results We are pleased to further inform you that the Board of Directors of the Company at its meeting held today, inter alia, have recommended a final dividend of Rs.11.50 per equity share, for the financial year ended June 30, 2022.29-08-2022
Procter & Gamble Health Ltd - 500126 - Compliances-Reg.24(A)-Annual Secretarial Compliance
Please find enclosed the annual secretarial compliance report for the year ended June 30, 2022, in line with SEBI Circular No. CIR/CFD/CMD1//27/2019 dated February 8, 2019.28-08-2022
Procter & Gamble Health Ltd - 500126 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Pursuant to regulation 39(3) of the SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015,we hereby inform you regarding issue of duplicate share certificate(s) to the shareholder(s) of the Company, on August 11,2022. We request you to take the same on record and acknowledge the receipt.12-08-2022